Therapeutic oncology company RefleXion Medical and 3B Pharmaceuticals have inked an exclusive licensing agreement for RefleXion to develop and commercialize a specific 3BP molecule for its Scintix biology-guided radiotherapy.
The companies said this molecule may expand the patient population eligible for Scintix therapy to patients with solid tumor cancers of any stage, as well as improve outcomes and procedural workflow. The molecule, called RXM-4768, targets fibroblast activation proteins found in nearly all solid tumor types. The companies selected it for RefleXion’s Scintix radiotherapy, which expands the role of such molecules to include directing external-beam radiotherapy delivery in real-time.
Under the terms of the agreement, RefleXion has worldwide, exclusive, and sublicensable rights to continue the development and subsequent commercialization of RXM-4768 for use with Scintix biology-guided radiotherapy. The terms also include upfront and annual license payments to 3B Pharmaceuticals. Additional payments and commercial royalties would also be due to 3B Pharmaceuticals upon achievement of certain regulatory and commercial milestones.
